WIGGANS THOMAS G — SEC Form 4 filings
SEC reporting owner CIK 1208907. 9 Form 4 filings on record with FilingPulse; latest filed 2026-08-04.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-01-26 to 2026-08-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 41,000 shares, $99,630 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: purchase of 41,000 shares @ $2.43 ($99,630) in Jasper Therapeutics, Inc., filed 2025-09-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | Director | 4 | 1 leg · 41,000 sh · $99,630 | — | 4 |
| CymaBay Therapeutics, Inc. (CBAY) | Director | 2 | — | — | 5 |
| Annexon, Inc. (ANNX) | Director | 2 | — | — | 2 |
| Pacira BioSciences, Inc. (PCRX) | Director | 1 | — | — | 1 |
Form 4 filings — WIGGANS THOMAS G
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Jasper Therapeutics, Inc. (JSPR) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 32,675 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Jasper Therapeutics, Inc. (JSPR) | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Jasper Therapeutics, Inc. (JSPR) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Jasper Therapeutics, Inc. (JSPR) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | CymaBay Therapeutics, Inc. (CBAY) | Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 67,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 14,010 (derivative) | EDGAR |
| 2024-01-26 | 4 | CymaBay Therapeutics, Inc. (CBAY) | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1208907 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →